CERU Cerulean Pharma Inc

Cerulean to Host Third Quarter 2016 Conference Call on November 3

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the third quarter 2016 on November 3.

Management will conduct a conference call at 4:30 p.m. ET that day to provide a business update and review the Company’s third quarter financial results. This call can be accessed by dialing (844) 831-3031 or (443) 637-1284 prior to the start of the call and referencing conference ID 7618037.

The conference call also will be webcast live over the Internet and can be accessed on the "Investors" section of the Cerulean website, www.ceruleanrx.com. The webcast will be archived on the Company's website for two weeks.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our first platform-generated NDC clinical candidate, CRLX101, is in clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit http://www.ceruleanrx.com/.

EN
27/10/2016

Underlying

CERUCerulean Pharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cerulean Pharma Inc

 PRESS RELEASE
Free
CERU Cerulean Pharma...

Cerulean Pharma and Daré Bioscience Announce Closing and New Stock Sy...

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience Operations, Inc. (formerly Daré Bioscience, Inc.) today announced the closing of the transactions contemplated by the stock purchase agreement entered into by the companies on March 19, 2017. As a result of these transactions, (i) the former holders of Daré equity securities now hold approximately 51% of Cerulean capital stock (calculated based on the stock purchase agreement), (ii) Daré Bioscience Operations, Inc. has become a wholly-...

July 19, 2017 1 EN
 PRESS RELEASE
Free
CERU Cerulean Pharma...

Daré Bioscience Distributes Letter to Cerulean Stockholders Outlining...

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience, Inc. today announced that Daré Founder and CEO Sabrina Martucci Johnson mailed the following letter to Cerulean stockholders of record at the close of business on June 9, 2017 outlining the Daré value proposition and requesting they vote FOR all of the management proposals at the upcoming special meeting of stockholders to be held on July 19, 2017: Dear Cerulean Stockholder, As the founder and CEO of Daré Bioscience,...

July 5, 2017 1 EN
 PRESS RELEASE
Free
CERU Cerulean Pharma...

Cerulean Urges Stockholders to Vote for Proposals at July 19, 2017 Spe...

WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) today urged stockholders of record at the close of business on June 9, 2017 to vote FOR all of the proposals at the upcoming special meeting of stockholders to be held on July 19, 2017. Each of the proposals is an important element of Cerulean’s plan to maximize stockholder value. On February 1, 2017, Cerulean announced its board of directors had initiated a review of strategic alternatives which could result in changes to its business strategy and future ...

June 27, 2017 1 EN
 PRESS RELEASE
Free
CERU Cerulean Pharma...

Cerulean Distributes Letter to Stockholders Requesting Favorable Vote ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU) today announced that the company mailed the following letter from President and Chief Executive Officer Christopher D. T. Guiffre to the company’s stockholders of record at the close of business on June 9, 2017, requesting they vote “for” all of the management proposals at the upcoming special meeting of stockholders to be held on July 19, 2017: Dear Fellow Cerulean Stockholder: Cerulean Pharma Inc. (“Cerulean”) respectfully requests your vote in ...

June 19, 2017 1 EN
 PRESS RELEASE
Free
CERU Cerulean Pharma...

Cerulean and Daré Announce Awards for Daré CEO

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), and Daré Bioscience, Inc., a privately-held, clinical-stage healthcare company advancing products for women’s reproductive health, today announced that Sabrina Martucci Johnson, Daré Founder and CEO, is receiving two awards. Ms. Johnson was honored by Athena, a San Diego-based business organization championing women executives and rising managers in science, technology, engineering and mathematics. “Recipients of the 2017 Pinnacle Awards represe...

May 8, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch